Hematology

Following three studies that examined its safety and efficacy, the FDA approves the first fecal microbiota product to prevent recurring Clostridioides difficle infection in patients.

Following three studies that examined its safety and efficacy, the FDA approves the first fecal microbiota product to prevent recurring Clostridioides difficle infection in patients.

Following three studies that examined its safety and efficacy, the FDA approves the first fecal microbiota product to prevent recurring Clostridioides difficle infection in patients.

Following three studies that examined its safety and efficacy, the FDA approves the first fecal microbiota product to prevent recurring Clostridioides difficle infection in patients.

The recent FDA approval of a new oral treatment for patients with amyotrophic lateral sclerosis (ALS) adds another option for individuals who are diagnosed with the non-curable disease.

The recent FDA approval of a new oral treatment for patients with amyotrophic lateral sclerosis (ALS) adds another option for individuals who are diagnosed with the non-curable disease.

The recent FDA approval of a new oral treatment for patients with amyotrophic lateral sclerosis (ALS) adds another option for individuals who are diagnosed with the non-curable disease.

The recent FDA approval of a new oral treatment for patients with amyotrophic lateral sclerosis (ALS) adds another option for individuals who are diagnosed with the non-curable disease.

The recent FDA approval of a new oral treatment for patients with amyotrophic lateral sclerosis (ALS) adds another option for individuals who are diagnosed with the non-curable disease.

To reduce the amount of tobacco-related disease and death in the United States, the FDA is proposing additional action on flavored cigarettes and cigars.